Flurbiprofen

Limits on what this shows

• Null and limiting findings: Mahmud 1996 [11] reports that modified flurbiprofen derivatives and nabumetone did not uncouple while conventional NSAIDs did (summarizer wording); the relation to parent flurbiprofen was not clear from the abstract. All flurbiprofen data are rat, in vitro, and at unspecified concentrations; no comparison with human plasma concentrations (above 99% protein bound [1]) was possible. No human or in vivo mitochondrial marker (lactate, muscle biopsy, respirometry) with flurbiprofen was found.

Regulatory status

The label retrieved [1] does not discuss mitochondrial effects.

Population evidence

Tier B, flurbiprofen in the cohort. Browne et al., Biochem Pharmacol 1999 [10]: by its title, ibuprofen, flurbiprofen and ketorolac inhibit hepatic mitochondrial beta-oxidation and oxidative phosphorylation in a stereoselective and substrate-dependent way (isolated rat hepatic mitochondria). Only the title and metadata were seen; the OpenAlex abstract was null, so concentrations and magnitude are unknown. Horie et al., J Pharmacol Exp Ther 1998 [9] (rat hepatocytes, 18 acidic NSAIDs, flurbiprofen named among the cytotoxic arylpropionic acids by a summarizing fetch of the PDF abstract): the authors attribute the hepatocellular ATP fall seen with the cytotoxic NSAIDs "probably" to uncoupling of mitochondrial oxidative phosphorylation. Flurbiprofen-specific effect size was not in the text read.

Mechanism

Named in the abstracts: inhibition of beta-oxidation and oxidative phosphorylation (title [10]) and probable uncoupling of oxidative phosphorylation (abstract [9]). The class concept that acidic NSAIDs uncouple oxidative phosphorylation is stated by Mahmud 1996 [11], but that abstract (read through an index record and summarizer) names modified flurbiprofen compounds that did not uncouple, not the parent drug, so it is not counted as flurbiprofen evidence.

Hard Rule 2 check

Mitochondrial toxicity in vitro is the drug acting on a structure, not a nutrient deficiency, and no cofactor (CoQ10, carnitine, B vitamins) was measured. Do not file as a coenzyme depletion.

Counter-evidence held on record

Counter-evidence and confounding In vitro concentrations in isolated mitochondria and hepatocytes are often well above those reached in plasma, and high protein binding lowers the free fraction; the clinical significance is unestablished. Hepatotoxicity of NSAIDs is rare relative to exposure (label: ALT or AST at least 3 times the upper limit in about 1% of NSAID-treated patients [1]). Framing caution Not a reason to take CoQ10, carnitine or any antioxidant. Treat as a laboratory signal tied to rare hepatotoxicity, not a measured energy deficit in patients.

Limits on what this shows

• Null and limiting findings: None showing pro-oxidant or antioxidant-depleting effects. All data are in vitro; direction is protective chemistry, not depletion.

Regulatory status

Not addressed in the label text retrieved [1].

Population evidence

Tier B in vitro, flurbiprofen in the cohort. Costa, Moutinho, Lima and Fernandes, Biol Pharm Bull 2006 [8] (abstract opened on J-STAGE): seven arylpropionic acid NSAIDs (ibuprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, naproxen, indoprofen) were screened against O2-, H2O2, HO, ROO, HOCl, NO and ONOO- in non-cellular systems and in human neutrophil oxidative burst. The abstract lists flurbiprofen in the rank orders for superoxide (fenbufen < flurbiprofen < indoprofen < ketoprofen), hydrogen peroxide, hydroxyl radical, peroxynitrite and neutrophil-derived ROS (ketoprofen > indoprofen > fenbufen > flurbiprofen), meaning flurbiprofen was active, and in several rankings weaker than other drugs. Concentrations and rate constants were not in the abstract.

Mechanism

Direct chemical scavenging of reactive species; the authors state the effects "if confirmed in vivo" may contribute to anti-inflammatory activity [8]. No glutathione, MDA or antioxidant enzyme measurement in flurbiprofen users was retrieved.

Hard Rule 2 check

A drug radical scavenging activity in a test tube is not a nutrient entry and does not imply any antioxidant vitamin need or benefit.

Counter-evidence held on record

Counter-evidence and confounding In vitro screens at test concentrations that may not be reached in vivo; NSAID oxidative effects in tissue (for example mitochondrial injury above) point the other way and were not measured for flurbiprofen. Framing caution Not evidence that flurbiprofen is antioxidant in patients, and not evidence of antioxidant depletion. No antioxidant supplement is implied.

Limits on what this shows

• Null and limiting findings: The Moore review states there is no direct evidence linking anemia with low-level bleeding into the bowel [7] (restated by the review as a limitation; read through a summarizer, so treat as paraphrase). The label gives anemia an incidence below 1% [1]. No flurbiprofen-specific hemoglobin series was found, and the clinical literature search channels were largely blocked (see Ungraded section and Sources).
• At-risk subgroups: Older adults, prior ulcer or GI bleeding, and concurrent warfarin (label: synergistic bleeding effect) or aspirin (label: aspirin lowers flurbiprofen serum concentrations by about 50%, an effect on the drug, not a protection) [1].

Regulatory status

Label (summarizing fetch, revision shown as July 2025; the DailyMed search [3] returned no label) [1]: serious GI bleeding is a labeled risk, with approximately 1% of NSAID-treated patients developing ulcers or bleeding during 3 to 6 months of therapy (summarizer wording of the class statement). Anemia: "Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis"; monitor hemoglobin or hematocrit if signs or symptoms of anemia occur, and consider periodic CBC and chemistry profile with long-term treatment. In the adverse reaction incidence lists, GI bleeding sits in the 1% or greater group and anemia in the under 1% group (summarizer wording; the tables were not read raw). The label text retrieved does not mention iron, vitamins or minerals [1].

Population evidence

None for flurbiprofen. Moore, Derry and McQuay 2008 [7] (Tier A design, systematic review of 47 randomized trials, 1,162 participants, autologous chromium-labelled erythrocytes): a summarizing fetch of the full text found flurbiprofen is NOT listed in the weighted mean fecal blood loss table; baseline was 0.46 mL/day and placebo 0.76 mL/day; the review states about 5% of NSAID takers lose 5 mL/day or more and 1% lose 10 mL/day or more (pooled across NSAIDs, not flurbiprofen). CLASS EXTRAPOLATION cohort test: flurbiprofen NOT in the cohort per that pass, so the class numbers are context only. The SOS meta-analysis of individual NSAIDs and upper GI complications [18] (abstract-level) names 16 NSAIDs and not flurbiprofen. The Han 2025 Korean cohort of NSAID subtypes and anemia [17] analyzed aceclofenac, meloxicam, loxoprofen, celecoxib and naproxen, not flurbiprofen. A Crossref title search for flurbiprofen with faecal blood loss returned unrelated InPharma records and no flurbiprofen blood loss paper.

Mechanism

Proposed, class-level: COX-1 and COX-2 inhibition with mucosal injury and occult bleeding; the label names blood loss, fluid retention and an incompletely described effect on erythropoiesis as possible anemia causes [1]. No flurbiprofen study of ferritin, iron absorption or iron turnover was retrieved.

Hard Rule 2 and 6 checks

GI bleeding and anemia are clinical outcomes, not iron deficiency; deficiency needs measured iron indices. Confounding by indication is presumed (rheumatic disease, age, aspirin or anticoagulant co-use). Direction is loss through bleeding, a toxicity route, not an absorption defect. Circulating claim: a Lima Memorial page states "Taking nonsteroidal anti-inflammatory drugs may deplete iron" and lists flurbiprofen (Ansaid, Ocufen) among 23 NSAIDs with no citation (Tier D) [20].

Counter-evidence held on record

Counter-evidence and confounding Flurbiprofen-specific bleeding magnitude is unknown here; blood loss varies widely between NSAIDs in controlled work, so numbers from other drugs cannot be assigned to flurbiprofen. Framing caution This is a toxicity pathway (blood loss), not a dietary or absorption deficiency. New iron deficiency or dark stools on flurbiprofen calls for evaluating the bleeding source and the prescription, not an iron supplement by default. No iron dose is recommended here.

Limits on what this shows

• Why no grade: Dual condition met after a fresh repair search. (1) No Tier B or C evidence for a copper status effect. The 1991 J Inorg Biochem paper (Oga, Taniguchi, Najjar, Souza) [19] was re-checked: a PubMed listing page showed its abstract, which reports that a synthesized copper(II) flurbiprofen complex had anti-inflammatory and analgesic properties comparable to free flurbiprofen in rats with less gastric irritation than the parent drug. This is a synthetic coordination complex made from the drug and copper: copper is the carrier in a new compound, the direction is copper acting on the drug's properties, and no copper status, absorption, excretion or ceruloplasmin measurement is involved, so it is not nutrient evidence and was not used as Tier B support. The Verheijden and van Miert 1985 ruminant mastitis review [25] (abstract reconstructed from OpenAlex) lists hypercupremia among nonspecific acute-phase responses and says flurbiprofen had a beneficial effect on experimental E. coli mastitis, but it does not state any flurbiprofen effect on copper; hypercupremia there is a disease response. The goat studies opened for zinc [22][23][24] report plasma iron and zinc, not copper. (2) No circulating claim: neither Lima Memorial [20], People's Pharmacy [21] nor the consumer label text [6] mentions copper for flurbiprofen.

Channels tried

Label text for copper, iron, zinc and minerals (none found) [1]. PubMed listing pages (format=pubmed): "flurbiprofen copper" (10 records, all irrelevant to copper status: the 1991 complex paper, a 2009 spectroscopic Cu(II) and Hg(II) flurbiprofen complex study, a 2018 flurbiprofen chalcone hybrid study with Cu(2+)-induced amyloid aggregation, a 1988 copper sulfate corneal vascularization rabbit model where flurbiprofen was an anti-inflammatory tool, a 1975 enzyme preparation note, analytical sensors and synthesis papers); "flurbiprofen plus ceruloplasmin or serum copper or trace elements or serum zinc" (one record, the 1985 mastitis review [25]); "flurbiprofen ceruloplasmin" (HTTP 404, no page returned); a NSAID plus serum copper plus rheumatoid query (HTTP 429). OpenAlex single-record lookups for PMIDs 2019832 (abstract null) and 3909626 (abstract reconstructed). Consumer pages [6][20][21]. Blocked or exhausted: WebSearch (shared per-turn budget exhausted), repeated PubMed listing 429 responses after the first few requests (retried only after waiting several minutes), Europe PMC, Semantic Scholar and OpenAlex search endpoints (not attempted again, previously 429), ScienceDirect and Springer search (robots disallowed).

Genuine gap or tooling-limited

Probably a genuine gap for copper status with flurbiprofen: the PubMed term searches that completed returned no copper status study with this drug, and the one animal disease paper lists hypercupremia without a flurbiprofen attribution. Partly tooling-limited because WebSearch was unavailable, several PubMed queries were rate-limited, and no full texts were opened (for example, whether the 1982 and 1994 goat papers measured copper is not visible in their abstracts). Re-check with working PubMed access (flurbiprofen with copper, ceruloplasmin, trace elements in humans) before treating it as closed.

Limits on what this shows

• Null and limiting findings: No significant alpha diversity change for NSAIDs as a class [15]; the ketorolac study found no significant diversity change either [13]. No flurbiprofen 16S, fecal microbiota or C. difficile outcome was retrieved.

Regulatory status

Not addressed in the label text retrieved [1].

Population evidence

All Tier C for flurbiprofen. Le Bastard et al., Aliment Pharmacol Ther 2018 [15] (systematic review, abstract reconstructed from OpenAlex): NSAIDs and metformin showed no significant alpha diversity change; beta diversity changed for all drugs studied except NSAIDs; NSAIDs, PPIs, metformin and opioids were linked to increases in Gammaproteobacteria or Enterococcaceae; flurbiprofen not named in the abstract. A 2009 Br J Nutr study [14] (16S sequencing, elderly NSAID users and non-users versus young adults; abstract reconstructed from OpenAlex) reported shifts in phyla and lower butyrate-producing taxa with age and NSAID use together; no specific NSAID named. A 4-week ketorolac rat study (Front Pharmacol 2021) [13] found no Shannon diversity change but loss of some Firmicutes families and increased Enterobacteriaceae at 3 mg/kg (n=10 per group); flurbiprofen not dosed. CLASS EXTRAPOLATION cohort test: flurbiprofen NOT in any of these.

Mechanism

Proposed: mucosal injury, altered bile acids and bacterial drug metabolism; the Maseda and Ricciotti 2020 review [16] states that NSAIDs inhibiting both COXs, including flurbiprofen, severely damage the small intestine in rodents (mucosal injury, not a microbiome measurement), and mentions microbial conversion of flurbiprofen by a fungus in a different context (summarizer wording, not relied on).

Hard Rule 6 check

Class extrapolation, capped at yellow, flurbiprofen not in the cohort of any source.

Counter-evidence held on record

Counter-evidence and confounding Age, disease, PPI co-use and diet are strong confounders in human NSAID studies, and the human study cannot attribute change to any individual NSAID. Framing caution A theoretical class signal only. No probiotic or prebiotic recommendation is implied.

Limits on what this shows

• Null findings: No arterial oxygenation, red-cell oxygen affinity or hemoglobin series with flurbiprofen was found.

Regulatory status

Label [1] (summarizing fetch): anemia statement and hemoglobin or hematocrit monitoring as above; hemolytic anemia listed under incidence below 1%; aplastic anemia and agranulocytosis listed among postmarketing experience (summarizer wording; frequency tables not read raw). Consumer label text lists "low red blood cells (anemia)" symptoms [6].

Population evidence

None measuring oxygen delivery. No flurbiprofen case report of hemolysis or methemoglobinemia was retrieved; the search channels tried are listed in the Ungraded section. Crossref title records titled only "Flurbiprofen" in Reactions Weekly (adverse reaction news items) exist for several years, but their text was not retrievable (OpenAlex abstracts null) and none is cited.

Mechanism

Three routes in the label and general pharmacology, none shown to lower oxygen delivery at therapeutic dosing: blood loss anemia (see Iron), fluid retention with dilution of hemoglobin concentration, and rare immune or marrow reactions listed in postmarketing experience [1].

Hard Rule 2 check

Anemia is an outcome, not a nutrient deficiency, and a drug reaction is an adverse event, not an oxygen-delivery deficiency. Flurbiprofen has no intended hemodynamic oxygen-demand effect to clarify. This entry is a context and monitoring flag only; the label basis is Tier A for the existence of the warning, not for any measured oxygen-delivery change, so the entry stays yellow.

Counter-evidence held on record

Counter-evidence and confounding Postmarketing reports have no denominator, and the label lists three possible anemia causes that are not oxygen-delivery mechanisms. Framing caution Do not read this as an oxygen-carrying deficiency that supplements can fix. Unexplained fatigue, pallor, jaundice or dark urine on flurbiprofen is a prescriber question; no iron, folate or antioxidant supplement is implied.

Limits on what this shows

• Null and limiting findings: No ATP, phosphocreatine or fatigue endpoint in flurbiprofen-treated humans was retrieved. In vitro cytotoxic concentration relative to plasma was not established.

Regulatory status

Not addressed in the label text retrieved [1].

Population evidence

Tier B, flurbiprofen in the cohort (group finding). Horie et al. 1998 [9], isolated rat hepatocytes, 18 acidic NSAIDs including flurbiprofen: "All of the cytotoxic NSAIDs and diphenylamine extensively decreased hepatocellular ATP content, whereas the noncytotoxic NSAID did not" (summarizer-quoted PDF abstract). Flurbiprofen was named among drugs causing LDH leakage; whether its own ATP value was reported was not visible in the text read. Concentrations and exposure time were not read.

Mechanism

Probable uncoupling of mitochondrial oxidative phosphorylation, as inferred by the authors [9]; the same body of evidence as the Mitochondrial burden entry.

Hard Rule 2 and 7 checks

Reduced ATP in injured cells is drug toxicity, not a nutrient deficiency; "low energy" is not graded as a symptom entry. This entry is separate from Mitochondrial burden and Oxygen delivery per Hard Rule 7 but is not independent evidence (see Overlap map).

Counter-evidence held on record

Counter-evidence and confounding Group-level finding from a single hepatocyte study; flurbiprofen-specific data were not extracted. Fatigue in treated patients is confounded by the underlying disease. Framing caution This is not evidence of an energy deficit that supplements can fix. No ATP, CoQ10 or carnitine recommendation is implied.